Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...

“I think that is reflective of how Express Scripts is moving forward.” The demonstration of hard clinical benefits and ROI for Express Scripts were the key elements that landed 10 digital platforms a spot on...

The Duke-Margolis Center for Health Policy has released a proposal that could remove the biggest barrier to the widespread adoption in the U.S. of value-based payment contracts for medicines. A technical fix to the Medicaid...

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients....

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...

Payers are starting to sort out how to reimburse for digital therapies and tools while they get up to speed on the new class of products. The answer is more of an “it depends” than...

A White House decision to withdraw a rule that would have eliminated rebates in Medicare Part D is the result of an internecine battle within the Trump administration over how to tackle drug pricing. It...

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...